肺癌免疫治疗预测生物标志物:国际肺癌研究协会病理委员会视角
国际肺癌研究协会病理委员会综述指出,免疫检查点抑制剂已成为晚期或转移性肺癌及早期新辅助/辅助治疗的主要手段,但仅部分患者有 meaningful 应答。PD-L1免疫组化作为主要预测标志物性能可能不理想且伴随诊断检测存在实践问题,TMB也有技术问题;新辅助免疫治疗相关新抗原、遗传与表观遗传特征、免疫微环境、微生物组及病理缓解等个体或联合标志物可能提供更好的应答与预后预测。
要点
- PD-L1免疫组化是主要预测标志物,但性能可能不理想且不同伴随诊断检测存在实践问题。
- TMB作为免疫检查点抑制剂预测标志物存在多项技术问题。
- 新抗原、遗传与表观遗传特征、免疫微环境、微生物组及新辅助免疫治疗病理缓解等标志物可能提供更好预测。
核心结论
- 本综述旨在强调PD-L1免疫组化与TMB之外新的个体或联合预测生物标志物的效能。
研究设计与样本
- 国际肺癌研究协会病理委员会发表的综述,概述多种免疫治疗生物标志物。
主要发现
- 免疫检查点抑制剂已成为大多数晚期或转移性肺癌的治疗骨干,并越来越多用于早期肿瘤的新辅助和辅助治疗。
- 仅一部分患者对免疫检查点抑制剂有有意义的应答。
- PD-L1免疫组化作为主要预测标志物,其性能可能不理想,且不同获批伴随诊断检测存在多项实践问题。
- TMB作为免疫检查点抑制剂预测标志物存在多项技术问题。
- 正在进行的肿瘤与宿主免疫特异性因子研究已识别出可能提供更好应答和预后预测的免疫治疗标志物,特别是在多模态方法中。
关键数值与推荐
- 综述涵盖PD-L1免疫组化与TMB的更新数据,以及新抗原、遗传与表观遗传特征、免疫组化与转录组学的免疫微环境、微生物组和新辅助免疫治疗病理缓解的评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In addition, they have increasingly been used for early stage tumors in neoadjuvant and adjuvant settings. Unfortunately, however, only a subset of patients experiences meaningful response to ICIs. Although programmed death-ligand 1 (PD-L1) protein expression by immunohistochemistry (IHC) has played a role as the principal predictive biomarker for immunotherapy, its performance may not be optimal, and it suffers multiple practical issues with different companion diagnostic assays approved. Similarly, tumor mutational burden (TMB) has multiple technical issues as a predictive biomarker for ICIs. Now, ongoing research on tumor- and host immune-specific factors has identified immunotherapy biomarkers that may provide better response and prognosis prediction, in particular in a multimodal approach. This review by the International Association for the Study of Lung Cancer Pathology Committee provides an overview of various immunotherapy biomarkers, including updated data on PD-L1 IHC and TMB, and assessments of neoantigens, genetic and epigenetic signatures, immune microenvironment by IHC and transcriptomics, and microbiome and pathologic response to neoadjuvant immunotherapies. The aim of this review is to underline the efficacy of new individual or combined predictive biomarkers beyond PD-L1 IHC and TMB.
引用
- Mino-Kenudson M, Schalper K, Cooper W, et al. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022. PMID: 36184066. doi:10.1016/j.jtho.2022.09.109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。